All In Biotech

Drug Trial Radar · NCT06912165

A Study of WD-890 in Participants With Moderate-to-Severe Plaque Psoriasis

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of WD-890 Tablets for the Treatment of Moderate to Severe Plaque Psoriasis

Last checked: Nov 19, 2026Latest source record: Apr 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 140 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

140

Planned (sponsor's estimate)

Start

Dec 31, 2024

Primary completion

Oct 30, 2025

Study completion Nov 30, 2025

Sponsor

Sponsor type
Industry
First posted
Apr 4, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Th purpose of the study is to evaluate the dose response of WD-890 in efficacy at Week 16 in participants with moderate-to-severe plaque psoriasis.

Conditions

  • Brief Description of Focus of Study

Interventions

  • WD-890 tabletDrug

    Participants will receive WD-890 Dose 1 QD and placebo from Week 0 through Week 16. Participants will receive placebo to maintain the blinding of dose regimens.

  • WD-890 tabletDrug

    Participants will receive WD-890 Dose 2 QD and placebo from Week 0 through Week 16. Participants will receive placebo to maintain the blinding of dose regimens.

  • WD-890 tabletDrug

    Participants will receive WD-890 Dose 3 QD and placebo from Week 0 through Week 16. Participants will receive placebo to maintain the blinding of dose regimens.

  • PlaceboDrug

    Participants will receive placebo QD from Week 0 through Week 16.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 75 Score at Week 16Time frame: Screening up to Week 16

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences, Peking Union Medical College

    Nanjing, Jiangsu, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.